RecruitingEarly Phase 1NCT07460232

FET PET/CT Imaging To Localize Pituitary Adenomas In Cushing Disease

18Fluoro-O-(2) Fluoroethyl-L-tyrosine (FET) PET For Localization Of Pituitary Adenomas In Patients With Cushing Disease

Sponsor

Mayo Clinic

Enrollment

50 participants

Start Date

Apr 27, 2026

Study Type

INTERVENTIONAL

Conditions

Pituitary Adenoma Cushing Disease

Summary

The purpose of this research is to evaluate the performance \[sensitivity, specificity, accuracy\] of FET PET/CT imaging to detect ACTH-secreting pituitary adenoma, using operative findings and histopathology as truth standard.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Fluoro-O-(2) fluoroethyl-L-tyrosine (FET) PET for people with cushing disease and pituitary adenoma. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGFluoro-O-(2) fluoroethyl-L-tyrosine (FET) PET

Patients will receive intravenous administration of radiolabeled FET (5mCi ±10%) administered 20 minutes (±10minutes) prior to the initiation of the attenuation correction CT followed by the PET acquisition encompassing the participant's head/neck, centered on the pituitary gland.